NCT02560272Unknown3 期
A Phase III, Double Blind, Parallel-controlled, Randomised Study to Evaluate the Safety and Immunogenicity of Haemophilus Influenzae Type b Conjugate Vaccine in Healthy Children 2 Months to 5 Years of Age
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 1,560
- 试验地点
- 1
- 主要终点
- Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to (≥) 0.15 Microgram Per Milliliter (µg/mL) and ≥ 1.0 µg/mL
研究概览
简要总结
The study will evaluate the safety and immunogenicity of a haemophilus influenzae type b conjugate vaccine (Hib) in Healthy Children 2 Months to 5 Years of Age who have not been previously immunized with a Hib vaccine. Children 2 to 5 months of age will receive 3 doses of Hib vaccine, Children 6 to 11 months of age will receive 2 doses of Hib vaccine, Children 1 to 5 years of age will receive 1 dose of Hib vaccine, with each dose given approximately 1 month apart.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 2 Months 至 5 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy permanent residence 2 months to 5 years old.
- •Subjects who the investigator believes will comply with the requirements of the protocol should be enrolled in the study.
- •Subjects and parent/guardian able to attend all scheduled visits and comply with all study procedures.
- •Axillary temperature ≤37.0 ℃.
排除标准
- •History of Haemophilus influenzae type b infection or vaccination of Haemophilus influenzae type b conjugate vaccine.
- •Allergic history or any SAE after vaccination, such as allergy, urticaria, dyspnea, angioedema, celialgia.
- •Receipt of blood or blood-derived products in the 3 months preceding vaccination
- •Participation in another clinical study investigating a vaccine, drug in the 30 days preceding vaccination.
- •Receipt of any live virus vaccine in the 15 days preceding vaccination.
- •Receipt of any subunit vaccine and inactivated vaccine in the 7 days before vaccination.
- •Febrile illness (temperature ≥ 38°C) in the 3 days or any acute illness/infection in the 7 days preceding vaccination.
- •Thrombocytopenia.
- •History of treatment for thyroid gland disease.
- •Functional or anatomic asplenia.
- •History of eclampsia, epilepsy, encephalopathy and mental disease or family disease.
- •Any condition that, in the judgment of investigator, may affect trial assessment.
结局指标
主要结局
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to (≥) 0.15 Microgram Per Milliliter (µg/mL) and ≥ 1.0 µg/mL
时间窗: 28 days after last dose of primary vaccination
次要结局
- Number of Subjects With Any Solicited Local and General Symptoms(Within 7 days after any vaccination)
- Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations(28 days after last dose of primary vaccination)
- Number of Subjects With Any Unsolicited Adverse Events (AEs)(Within 28 days after any vaccination)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese ChildrenMeningitis, Epiglottitis, Pneumonia, Arthritis Caused by Haemophilus Influenzae Type bNCT02139228Novartis Vaccines426
已完成
4 期
The Safety and Immunogenicity of Haemophilus Influenzae Type b Vaccine in Different Injection SiteHealthyNCT01761136Beijing Center for Disease Control and Prevention680
已完成
1 期
Nontypeable H. Influenzae in Healthy AdultsHaemophilus Influenzae (NTHI)NCT00905385National Institute of Allergy and Infectious Diseases (NIAID)15
已完成
3 期
Immunogenicity and Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Infants and ChildrenGroup A, C Polysaccharide MeningitisType b Haemophilus InfluenzaNCT01428908Jiangsu Province Centers for Disease Control and Prevention2,394
已完成
3 期
Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type bHaemophilus Influenzae Type bNCT00808392Novartis Vaccines916